Chou et al., “Expression of Chimeric Monomer and Dimer Proteins on the Plasma Membrane of Mammalian Cells”, pp. 160-169, Biotechnology and Bioengineering, vol 65, No. 2, Oct. 20, 1999. |
Liao et al., “Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells”, pp. 339-347, Gene Therapy (2000) 7. |
Kulkarni et al., “Programmed Cell Death Signaling Via Cell-Surface Expression of a Single-Chain Antibody Transgene”, pp. 1209-1217, Transplantation, vol. 69, No. 6, Mar. 27, 2000. |
Kontermann et al., “Intracellular and cell surface displayed single-chain diabodies”, pp. 179-188, Journal of Immmunological Methods 226 (1999). |
Rode et al., “T cell activation by monoclonal antibodies bound to tumor cells by a cell surface displayed single-chain antibody”, pp. 151-160, Journal of Immunological Methods 224 (1999). |
Chesnut et al., “Selective isolation of transiently transfected cells from a mammalian cell population with vectors expressing a membrane anchored single-chain antibody”, pp. 17-27, Journal of Immunological Methods 193 (1999). |
Ines et al., “Apoptosis of a Human Melanoma Cell Line Specifically Induced by Membrane-Bound Single-Chain Antibodies”, pp. 3948-3956, Journal of Immunological Methods 163 (1999). |
Yang et al., “Antitumor Immunity Elicited by Tumor Cells Transfected with B7-2, a Second Ligand for CD28/CTLA-4 Costimulatory Molecules”, pp. 2794-2800, Journal of Immunological Methods 154 (1995). |
Griffin et al. “Blockade of T Cell Activation Using a Surface-Linked Single-Chain Antibody to CTLA-4 (CD152)”, pp. 4433-4442, Journal of Immunological Methods 164 (2000). |
Alvarez-Vallina et al., “Antigen-Specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors”, pp. 2304-2309, Eur. J. Immunol. 26 (1996). |
Brocker et al., “New simplified molecular design for functional T cell receptor”, pp. 1435-1439, Eur. U. Immunol. 23 (1993). |
“Cell Surface Display of a Single-Chain Antibody for Attaching Polypeptides”, pp. 650-658, BioTechniques vol. 21, No. 4 (1996). |
Freeman et al., “Murine B7-2, an alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production”, pp. 2185-2192, The Journal of Experimental Medicine, vol. 178, Dec. 1993. |
Tibben et al., “Pharmacokinetics, Biodistribution and Biological Effects of Intravenously Administered Bispecific Monoclonal Antibody OC/TR F9(ab′)2 In Ovarian Carcinoma Patients”, pp. 477-483, Int. J. Cancer: 66, (1996). |
Chen et al., “Tumor Immunogenicity Determines the Effect of B7 Costimulation on T Cell-mediated Tumor Immunity”, pp. 523-532, J. Exp. Med. © The Rockefeller University Press. vol. 179 Feb. (1994). |
Moritz et al., “Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells”, pp. 4318-4322, Proc. Natl. Acad. Sci. USA vol. 91, May 1994. |
Krause et al., “Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes”, pp. 619-626, J. Exp. Med © The Rockefeller University Press. vol. 188, No. 4, Aug. 17, 1998. |
Altenschmidt et al., “Specific cytotoxic T lymphocytes in gene therapy”, pp. 259-266, J. Mol. Med. 75 (1997). |
Altenschmidt et al., “Adoptive Transfer of In Vitro-Targeted, Activated T Lymphocytes Results in Total Tumor Regression”, pp. 5509-5515, The Journal of Immunology, 159, (1997). |